anti-CD4 (mouse), mAb (GK1.5) (preservative free)
| Code | Size | Price |
|---|
| ANC-704-820-100ug | 100 ug | £208.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: Rat IgG2bkappa
Antibody Clonality: Monoclonal
Antibody Clone: GK1.5
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Fluorescence-activated cell sorting (FACS)
- Functional Study
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
Shipping:
BI
Storage:
+4°C
Documents
Further Information
EClass:
32160000
Form (Short):
liquid
Formulation:
50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl.
Handling Advice:
Avoid freeze/thaw cycles.
Immunogen:
Mouse CTL-V4 membrane prep.
Long Description:
Monoclonal antibody. Binds to an extracellular epitope of the 55kd CD4 molecule present on a murine T cell subset. Applications: ELISA, FACS, FUNC, IHC, IP. Isotype: Rat IgG2bkappa. Clone: GK1.5. 50mM Sodium Phosphate pH 7.5, 100mM Potassium Chloride, 150mM NaCl. CD4 binds to MHC Class II expressed by antigen presenting cells, facilitating T cell receptor signaling.
Package Type:
Plastic Vial
Product Description:
CD4 binds to MHC Class II expressed by antigen presenting cells, facilitating T cell receptor signaling.
Purity:
>95% (SDS-PAGE)
Source / Host:
Rat
Specificity:
Binds to an extracellular epitope of the 55kd CD4 molecule present on a murine T cell subset.
Transportation:
Non-hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
References
Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines: D.B. wilde, et al.; J. Immunol. 131, 2178 (1983)
| Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule: D.P. Dialynas, et al.; J. Immunol. 131, 2445 (1983)
| Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology: J.H. Vernooy, et al.; Am. J. Respir. Cell Mol. Biol. 26, 152 (2002)
| Suppression of Alkali Burn-Induced Corneal Neovascularization by Dendritic Cell Vaccination Targeting VEGF Receptor 2: H. Mochimaru, et al.; IOVS 49, 2172 (2008)
Related Products
| Product Name | Product Code | Supplier | anti-CD4 (human), mAb (QS4120) | ANC-147-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| anti-CD4 (human), mAb (M-T441) | ANC-148-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD4 (mouse), mAb (GK1.5) (Biotin) | ANC-704-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD4 (mouse), mAb (GK1.5) (FITC) | ANC-704-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD4 (mouse), mAb (GK1.5) (R-PE) | ANC-704-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD4 (mouse), mAb (GK1.5) (APC) | ANC-704-060 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| anti-CD4 (mouse), mAb (GK1.5) (PE-Cy7) | ANC-704-070 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||